Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | PRKX | P51817 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MARK3 | P27448 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203492 | 1.00 | GAA (0.43) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6203493 | 1.00 | GAA (0.43) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6496765 | 0.95 | GAA (0.43) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6496760 | 0.95 | GAA (0.43) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6502173 | 0.92 | GAA (0.42) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6502171 | 0.92 | GAA (0.42) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6499819 | 0.92 | ROCK1 (0.42) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6201437 | 0.92 | ROCK1 (0.42) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6499827 | 0.92 | ROCK1 (0.42) | GAAROCK2ROCK1CYP3A4CYP2C9 | |
| SCHEMBL6499821 | 0.92 | ROCK1 (0.42) | GAAROCK2ROCK1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581498-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | claimed |
| US-6900210-B2 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | claimed |
| WO-2004047739-A2 | PYRIDINYL, PYRIMIDINYL AND PYRAZINYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | claimed |
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-27 | — | — | US | claimed |
| US-6900210-B2 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102449-A1 | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers | KCNQ5, KCNQ2, KCNQ3 | GAA 4438/4885ROCK2 3350/4885ROCK1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.